Pooled patients treated with TTI-101 demonstrated a 9.4% decrease from baseline in fibrosis score at week 12, compared to a 2 ...

First patients dosed in budoprutug PrisMN Phase 2 trial in pMN, with initial data expected second half 2026 Dosing ongoing in ...

44 th Annual J.P. Morgan Healthcare Conference Format: Company presentation Date: Thursday, January 15, 2026 Time: 12:00 PM PT Location: California East at The Westin St. Francis ...

Doctors at Fortis Hospital successfully performed a rare hybrid cardiac surgery on a 29-year-old man suffering from a ...

The FDA has granted breakthrough therapy designation to privosegtor for optic neuritis, a common symptom of multiple ...

The data showed that for every 10-unit increase in the Air Quality Index (AQI), cardiovascular events jumped by 1.8 per cent.

First patients dosed in budoprutug PrisMN Phase 2 trial in pMN, with initial data expected second half 2026 Dosing ongoing in budoprutug Phase 1b/2a trial in ITP and Phase 1b trial in SLE; achieved ...

Initial AX-0810 data show no safety signals after 4 weeks of dosing and pharmacokinetics consistent with non-clinical data; Phase 1 enrollment and dosing in healthy volunteers ongoing with target ...

A new review found that light to moderate intensity exercise may be better in tackling depression than vigorous exercise ...

Victoria Gray spent 34 years battling the debilitating pain of sickle cell disease. Then she volunteered to be the world's ...

AbolerIS Pharma ("AbolerIS"), a clinical-stage biopharmaceutical company committed to improving the lives of people suffering from autoimmune and inflammatory diseases, announced today that the first ...

Exercise may be just as good at treating depression as psychological therapies and possibly even antidepressants, a study suggests. A review of 73 studies from researchers at the University of ...